GSK, Pfizer Looking To Realise Cost Savings Of £500m Per Annum From Tie-Up
GlaxoSmithKline has announced the completion of its tie-up with Pfizer's consumer health portfolio, adding that the joint venture is expected to realise annual cost savings of £500 million (€549 million) by 2022.
The joint venture brings together GSK's portfolio of consumer healthcare brands, such as Sensodyne, Voltaren and Panadol with Pfizer's Advil, Centrum and Caltrate, among others.
GSK will own a 68% stake in the joint venture, while Pfizer will own 32%. It will continue to be led by GSK Consumer Healthcare CEO Brian McNamara.
Try European Supermarket Magazine PREMIUM – 30 Day FREE Trial.
A trial subscription gives unrestricted access to all premium site content, app content, weekly email content and European Supermarket Magazine digital edition for a full 30 days. Try it now!